1. Alavian F, Alavian K, Ghiasvand S, Rezaeian L. Protective Effects of Cherry Extract on Malondialdehyde Levels, Catalase Activity, and Edema Induced by Middle Cerebral Artery Occlusion in a Rat Stroke Model. The Neuroscience Journal of Shefaye Khatam. 2020; 8(3): 1-9. [DOI:10.29252/shefa.8.3.1]

2. Ahmadi M, Banazadeh Dardashti M, Karimzadeh F. The anti-aggressive effect of music therapy in an animal model of schizophrenia. The Neuroscience Journal of Shefaye Khatam. 2014; 2(1):51-5. [DOI:10.18869/acadpub.shefa.2.1.51]

3. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophrenia bulletin. 2009; 35(3): 493-508. [DOI:10.1093/schbul/sbp017]

4. Hintze B, Borkowska A. Intensity of negative symptoms, working memory and executive functions disturbances in schizophrenic patients in partial remission period. Psychiatria Polska. 2011; 45(4): 457-67.

5. Ben-Azu B, Aderibigbe AO, Eneni A-EO, Ajayi AM, Umukoro S, Iwalewa EO. Morin attenuates neurochemical changes and increased oxidative/nitrergic stress in brains of mice exposed to ketamine: prevention and reversal of schizophrenia-like symptoms. Neurochemical Research. 2018; 43(9): 1745-55. [DOI:10.1007/s11064-018-2590-z]

6. Xu K, Lipsky RH. Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans. Experimental Biology and Medicine. 2015; 240(2): 145-55. [DOI:10.1177/1535370214549531]

7. Leri M, Scuto M, Ontario ML, Calabrese V, Calabrese EJ, Bucciantini M, et al. Healthy effects of plant polyphenols: molecular mechanisms. International journal of molecular sciences. 2020; 21(4): 1250. [DOI:10.3390/ijms21041250]

8. Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chemistry. 2019; 299: 125124. [DOI:10.1016/j.foodchem.2019.125124]

9. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide‐induced neurotoxicity by inhibiting microglia activation. European Journal of Neuroscience. 2002; 16(11): 2103-12. [DOI:10.1046/j.1460-9568.2002.02290.x]

10. Ghosh A, Ghosh T, Jain S. Silymarin-a review on the pharmacodynamics and bioavailability enhancement approaches. Journal of Pharmaceutical Science and Technology. 2010; 2(10): 348-55.

11. Afjeh Dana E, Marivani M, Mehravi B, Karimzadeh F, Ashtari K. Development of Nanoparticles for Drug Delivery to the Brain. The Neuroscience Journal of Shefaye Khatam. 2017; 5(2): 76-87. [DOI:10.18869/acadpub.shefa.5.2.76]

12. Ali A, Ahmed S. A review on chitosan and its nanocomposites in drug delivery. International journal of biological macromolecules. 2018; 109: 273-86. [DOI:10.1016/j.ijbiomac.2017.12.078]

13. Moghaddam AH, Maboudi K, Bavaghar B, Sangdehi SRM, Zare M. Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neuroscience Letters. 2021; 765: 136249. [DOI:10.1016/j.neulet.2021.136249]

14. Moghaddam AH, Sangdehi SRM, Ranjbar M, Hasantabar V. Preventive effect of silymarin-loaded chitosan nanoparticles against global cerebral ischemia/reperfusion injury in rats. European Journal of Pharmacology. 2020; 877: 173066. [DOI:10.1016/j.ejphar.2020.173066]

15. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cognitive processing. 2012; 13(2): 93-110. [DOI:10.1007/s10339-011-0430-z]

16. Olson BJ, Markwell J. Assays for determination of protein concentration. Current Protocols in Pharmacology. 2007; 38(1): A. 3A. 1-A. 3A. 29. [DOI:10.1002/0471141755.pha03as38]

17. Genet S, Kale RK, Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonella foenum graecum). Molecular and cellular biochemistry. 2002; 236(1): 7-12. [DOI:10.1023/A:1016103131408]

18. Romero FJ, Romá J, Bosch-Morell F, Romero B, Segura-Aguilar J, Llombart-Bosch A, et al. Reduction of brain antioxidant defense upon treatment with butylated hydroxyanisole (BHA) and Sudan III in Syrian golden hamster. Neurochemical research. 2000; 25(3): 389-93. [DOI:10.1023/A:1007549222553]

19. Kim MS, Lee JI, Lee WY, Kim SE. Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2004; 18(8): 663-6. [DOI:10.1002/ptr.1486]

20. Demir M, Amanvermez R, Polat AK, Karabıçak I, Cınar H, Kesicioğlu T, et al. The effect of silymarin on mesenteric ischemia-reperfusion injury. Medical Principles and Practice. 2014; 23(2): 140-4. [DOI:10.1159/000356860]

21. Urban-Kowalczyk M, Pigońska J, Śmigielski J. Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms. Neuropsychiatric disease and treatment. 2015; 11: 2023. [DOI:10.2147/NDT.S87666]

22. Hauser MJ, Isbrandt D, Roeper J. Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. Behavioural brain research. 2017; 332: 316-26. [DOI:10.1016/j.bbr.2017.06.013]

23. Białoń M, Żarnowska M, Antkiewicz-Michaluk L, Wąsik A. Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. Psychopharmacology. 2020; 237(6): 1577-93. [DOI:10.1007/s00213-020-05484-1]

24. Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J-i, et al. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Behavioural brain research. 2015; 278: 186-92. [DOI:10.1016/j.bbr.2014.09.046]

25. Coronel‐Oliveros CM, Pacheco‐Calderón R. Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. Developmental psychobiology. 2018; 60(1): 30-42. [DOI:10.1002/dev.21586]

26. Fan N, Luo Y, Xu K, Zhang M, Ke X, Huang X, et al. Relationship of serum levels of TNF-α, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers. Schizophrenia research. 2015; 169(1-3): 10-5. [DOI:10.1016/j.schres.2015.11.006]

27. Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian journal of medical research. 2006; 124(5): 491.

28. Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine. 2020; 79: 153320. [DOI:10.1016/j.phymed.2020.153320]

29. Younis N, Shaheen MA, Abdallah MH. Silymarin-loaded Eudragit® RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. Biomedicine & Pharmacotherapy. 2016; 81: 93-103. [DOI:10.1016/j.biopha.2016.03.042]

30. Hajizadeh Moghaddam A. The protective effect of quince (Cydonia oblonga Miller) leaf extract on locomotor activity and anxiety-like behaviors in a ketamine model of schizophrenia. Journal of Arak University of Medical Sciences. 2016; 19(5): 31-41.

31. Kuen CY, Fakurazi S, Othman SS, Masarudin MJ. Increased loading, efficacy and sustained release of silibinin, a poorly soluble drug using hydrophobically-modified chitosan nanoparticles for enhanced delivery of anticancer drug delivery systems. Nanomaterials. 2017; 7(11): 379. [DOI:10.3390/nano7110379]